US EditionPublished • loading... • Updated
Fungal Vaccine Effort Gets $40 Million Federal Boost
The $40 million NIH award supports advancing VXV-01, a dual-antigen vaccine targeting resistant Candida infections in hospitalized and immunocompromised patients to Phase I trials.
Candida species are an increasing cause of invasive fungal disease, particularly in hospitalized and immunocompromised populations. Not only is the arsenal of antifungal medicines and vaccines limited, but emerging resistance—most notably among Candida auris and Candida albicans—contributes to increasing morbidity and mortality rates. There is an urgent need for new therapeutic strategies targeting Candida infections. Now, the Lundquist Institut…
9 Articles
9 Articles
Globe Newswire+7 Reposted by 7 other sources
The Lundquist Institute and its start-up company Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID
Los Angeles, CA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to...
Fungal Vaccine Effort Gets $40 Million Federal Boost
Candida species are an increasing cause of invasive fungal disease, particularly in hospitalized and immunocompromised populations. Not only is the arsenal of antifungal medicines and vaccines limited, but emerging resistance—most notably among Candida auris and Candida albicans—contributes to increasing morbidity and mortality rates. There is an urgent need for new therapeutic strategies targeting Candida infections. Now, the Lundquist Institut…
Coverage Details
Total News Sources9
Leaning Left6Leaning Right1Center1Last UpdatedBias Distribution75% Left
Bias Distribution
- 75% of the sources lean Left
75% Left
L 75%
13%
12%
Factuality
To view factuality data please Upgrade to Premium
